Kimia Farma, South Korea’s SungWun building $10.2M API facility in Indonesia


Kimia Farma, which is owned by the Indonesian government, and South Korea’s SungWun Pharmacopia are teaming up to build a $10.2 million API facility expected to begin operations in 2018.

The 16,400-square-foot facility will initially be able to produce 30 tons of 8 types of API for medicines per year with 23 of those tons slotted for export, the Jakarta Post reported. The plant will also produce 7 types of high function chemicals annually for use in cosmetics and food supplements.

The joint venture is called Kimia Farma Sungwun Pharmacopia.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

“At present, the country’s pharmaceutical industry uses around 2,200 types of API,” Rusi Rosman, Kimia Farma’s president director, said. “We aim to produce 50% of them within the next 10 years.”

Additional expansion over the next decade is planned to accommodate the goal set down by Rosman.

Currently, India and China are the two largest suppliers of pharmaceutical raw materials to Indonesia, followed by the U.S. and Europe.

-check out the Jakarta News story

Related article:
B. Braun Medical lands $33M loan to build sterile injection plant in Indonesia

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.